Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06197295 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 9, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 100 to 200
    • Primary completion date: Jun 15, 2025 to Jun 30, 2026
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    v6
  2. Re-verified, no change to tracked fieldsv5
  3. Primary completion date: Jun 15, 2024 to Jun 15, 2025
    • Study completion date: Dec 31, 2024 to Dec 31, 2025
    v4
  4. Enrollment target: 50 to 100v3
  5. Secondary endpoints: details revised at 4 of 4 entries
    • Eligibility criteria expanded, about 2 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.
Trial Details
NCT Number NCT06197295
Lead Sponsor Mackay Memorial Hospital
Conditions
(from sponsor)		 Urinary Bladder, Overactive, Effect of Drug
Related terms Urinary Bladder, Overactive
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov